Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018 / 2019 / Maladies chroniques et traumatismes / Rapports et synthèses / Publications et outils / Accueil, 2019. ,
Screening for Ovarian Cancer, JAMA [Internet], vol.319, issue.6, p.588, 2018. ,
Survie des personnes atteintes de cancer en France métropolitaine 1989-2013 -Partie 1 : tumeurs solides, 2016. ,
, Les cancers en France en 2018 -L'essentiel des faits et chiffres (édition 2019) -Ref : ETKAFR19 [Internet, 2019.
WHO classification of tumours of female reproductive organs, 2014. ,
Epidemiology of ovarian cancer: a review, 2017. ,
The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma, Gynecol Oncol, vol.152, issue.2, pp.426-459, 2019. ,
,
Incessant ovulation and ovarian cancer -a hypothesis re-visited. Facts, views Vis ObGyn, vol.5, pp.292-299, 2013. ,
Oral Contraceptive Pills as Primary Prevention for Ovarian Cancer, Obstet Gynecol, 2013. ,
, , vol.122, pp.139-186, 2019.
Cell Origins of High-Grade Serous Ovarian Cancer. Cancers (Basel) [Internet], vol.10, p.433, 2018. ,
The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol, 1999. ,
Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract, Nat Med, vol.11, issue.5, pp.531-538, 2005. ,
Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer, Carcinogenesis, vol.35, issue.3, p.491, 2003. ,
Serous tubal intraepithelial neoplasia: the concept and its application, vol.30, pp.710-731, 2017. ,
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer, J Pathol, vol.195, issue.4, pp.451-457, 2001. ,
A candidate precursor to serous carcinoma that originates in the distal fallopian tube, J Pathol, vol.211, issue.1, pp.26-35, 2007. ,
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship, Am J Surg Pathol, vol.31, issue.2, pp.161-170, 2007. ,
High grade serous ovarian carcinomas originate in the fallopian tube, Nat Commun, vol.8, issue.1, p.1093, 2017. ,
Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas, J Pathol, vol.246, issue.3, pp.344-51, 2009. ,
Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models. Cancer Cell, vol.24, pp.751-65, 2013. ,
The Li-Fraumeni syndrome (LFS): a model for the initiation of p53 signatures in the distal Fallopian tube, J Pathol, vol.220, issue.1, pp.17-23, 2010. ,
The genetics of ovarian cancer, Best Pract Res Clin Obstet Gynaecol, vol.16, issue.4, pp.449-68, 2002. ,
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing, Proc Natl Acad Sci, vol.108, issue.44, pp.18032-18039, 2011. ,
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1, Science ,
Identification of the breast cancer susceptibility gene BRCA2, Nature, vol.378, issue.6559, pp.789-92, 1995. ,
Breast-Cancer Risk in Families with Mutations in PALB2, N Engl J Med, vol.371, issue.6, pp.497-506, 2014. ,
Cancer Risks Associated With Germline Mutations in MLH1 MSH2 MSH6 Genes in Lynch Syndrome, JAMA, vol.305, issue.22, p.2304, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00780536
The Role in Genome Stability, Cancer Stemness and Therapy Resistance, J Cancer, vol.10, 2019. ,
Associations between BRCA Mutations in High-Risk Breast Cancer Patients and Familial Cancers Other than Breast or Ovary, J Breast Cancer, vol.15, issue.3, pp.283-290, 2012. ,
The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses, Current Protocols in Bioinformatics ,
, , 2016.
, , vol.33
The neXtProt knowledgebase on human proteins: 2017 update, Nucleic Acids Res, vol.45, issue.D1, pp.177-82, 2017. ,
BRCA1 and BRCA2: different roles in a common pathway of genome protection HHS Public Access, 2019. ,
BRCA Exchange as a global resource for variants in BRCA1 and BRCA2, vol.14, p.1007752, 2018. ,
Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations, Eur J Hum Genet, 2013. ,
, , vol.21, pp.212-218, 2019.
On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations, Eur J Hum Genet, vol.19, issue.3, pp.300-306, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00828528
BRCA1 and BRCA2 mutation spectrum -an update on mutation distribution in a large cancer genetics clinic in Norway, Hered Cancer Clin Pract, vol.16, issue.1, 2018. ,
Genome maintenance mechanisms for preventing cancer, Nature ,
Microhomology-mediated end joining: Good, bad and ugly ,
Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer, Annu Rev Cancer Biol [Internet], vol.2, issue.1, pp.313-349, 2018. ,
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers, JAMA, vol.317, issue.23, p.2402, 2017. ,
Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene, Nat Genet, vol.42, issue.5, pp.410-414, 2010. ,
Germline RAD51C mutations confer susceptibility to ovarian cancer, Nat Genet, vol.44, issue.5, pp.475-481, 2012. ,
Contribution of Germline Mutations in the RAD51B , RAD51C , and RAD51D Genes to Ovarian Cancer in the Population, J Clin Oncol, vol.33, issue.26, pp.2901-2908, 2015. ,
Germline mutations in RAD51D confer susceptibility to ovarian cancer, Nat Genet, 2011. ,
BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function, vol.105, pp.149-60, 2001. ,
Mutations in BRIP1 confer high risk of ovarian cancer, Nat Genet, vol.43, issue.11, pp.1104-1111, 2011. ,
BRIP1 loss-offunction mutations confer high risk for familial ovarian cancer, but not familial breast cancer, Breast Cancer Res [Internet], vol.20, issue.1, 2018. ,
Recommandations françaises du Groupe Génétique et Cancer pour l'analyse en panel de gènes dans les prédispositions héréditaires au cancer du sein ou de l'ovaire. Bull Cancer [Internet], vol.105, pp.907-924, 2018. ,
Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation, JAMA, vol.296, issue.2, p.185, 2006. ,
, Femmes porteuses d'une mutation de BRCA1 ou BRCA2 / Détection précoce du cancer du sein et des annexes et stratégies de réduction du risque -Ref : RECOBRCA17
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations, Gynecol Oncol, vol.97, issue.2, pp.457-67, 2005. ,
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality, JAMA -J Am Med Assoc, vol.304, issue.9, pp.967-75, 2010. ,
Screening for Ovarian Cancer, JAMA [Internet], vol.319, issue.6, p.595, 2018. ,
Les acides nucléiques du plasma sanguin chez l'homme. C R Seances Soc Biol Fil, vol.142, pp.241-244, 1948. ,
Free DNA in the serum of cancer patients and the effect of therapy, Cancer Res, vol.37, issue.3, pp.646-50, 1977. ,
Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease, vol.51, pp.2116-2136, 1983. ,
Neoplastic characteristics of the DNA found in the plasma of cancer patients, Oncology, vol.46, issue.5, pp.318-340, 1989. ,
Point mutations of the Nras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia, Br J Haematol, vol.86, issue.4, pp.774-783, 1994. ,
Soluble Normal and Mutated DNA Sequences from Single-Copy Genes in Human Blood", Nat Rev Cancer, 1994. ,
Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease, Nat Commun, vol.9, issue.1, 2018. ,
Direct detection of early-stage cancers using circulating tumor DNA, Sci Transl Med, vol.9, issue.403, p.2415, 2017. ,
Enhanced detection of circulating tumor DNA by fragment size analysis, Sci Transl Med [Internet], vol.10, issue.466, p.4921, 2018. ,
Origins, structures, and functions of circulating DNA in oncology, Cancer Metastasis Rev, vol.35, issue.3, pp.347-76, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02299112
Detection of circulating tumor DNA in early-and late-stage human malignancies, Sci Transl Med, vol.6, issue.224, pp.224-248, 2014. ,
Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing, vol.13, p.197333, 2018. ,
Isolation and characterization of DNA from the plasma of cancer patients, Eur J Cancer Clin Oncol, 1987. ,
Detection and localization of surgically resectable cancers with a multi-analyte blood test, Science [Internet], vol.359, issue.6378, pp.926-956, 2018. ,
A combination of circulating miRNAs for the early detection of ovarian cancer, Oncotarget, vol.8, issue.52, pp.89811-89834, 2017. ,
The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer, Genome Med, vol.9, issue.1, p.116, 2017. ,
Integrated genomic analyses of ovarian carcinoma, Nature, vol.474, issue.7353, pp.609-624, 2011. ,
Cell-free DNA: Preanalytical variables, Clinica Chimica Acta. Elsevier B.V, vol.450, pp.243-53, 2015. ,
Wholegenome characterization of chemoresistant ovarian cancer, Nature, vol.521, issue.7553, pp.489-94, 2015. ,
Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes, Nat Genet, vol.49, issue.6, pp.856-65, 2017. ,
A robust model for read count data in exome sequencing experiments and implications for copy number variant calling, Bioinformatics, vol.28, issue.21, pp.2747-54, 2012. ,
Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, Genet Med, vol.17, issue.5, pp.405-429, 2015. ,
Utilization of the oncoscan microarray assay in cancer diagnostics, Appl Cancer Res, vol.37, issue.1, 2017. ,
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of, Cancer. Cell, vol.173, issue.2, pp.291-304, 2018. ,
Detection of copy number alterations in cell-free tumor DNA from plasma. BBA Clin, vol.7, pp.120-126, 2017. ,
Ultra-Sensitive TP53 Sequencing for Cancer Detection Reveals Progressive Clonal Selection in Normal Tissue over a Century of Human Lifespan, Cell Rep, vol.28, issue.1, pp.132-144, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02180268
Accurate clinical detection of exon copy number variants in a targeted NGS panel using DECoN. Wellcome Open Res, vol.1, 2016. ,
Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial, J Clin Oncol, vol.34, pp.5549-5549, 2016. ,
,
, Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer, J Clin Oncol, vol.35, issue.12, pp.1274-80, 2017.
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma, Cancer Discov, vol.9, issue.2, pp.210-219, 2018. ,
Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers, PLoS One, vol.10, issue.12, 2015. ,
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study, 2016. ,
Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma, J Gynecol Oncol, vol.30, issue.3, 2019. ,
Copy number signatures and mutational processes in ovarian carcinoma, Nat Genet [Internet], vol.50, issue.9, pp.1262-70, 2018. ,
Massively parallel sequencing of cell-free DNA in plasma for detecting gynaecological tumour-associated copy number alteration Correction: Publisher Correction, vol.8, p.11205, 2018. ,
Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses, Clin Cancer Res, 2017. ,
Integrated Analyses of microRNAs Demonstrate Their Widespread Influence on Gene Expression in High-Grade Serous Ovarian Carcinoma, PLoS One ,
, , vol.7, p.34546, 2019.
, Mutations TP53 de faible fréquence allélique : peut-on s'affranchir de la biopsie pour différencier une mosaïque d'une hématopoïèse clonale ? In: Assise de génétique 2020, 2020.
Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy, p.2020, 2019. ,
,
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy, Cell Stem Cell, vol.23, issue.5, pp.700-713, 2018. ,
, en présence des maîtres de la Faculté, des conseillers de l'ordre des Pharmaciens et de mes condisciples
, D'honorer ceux qui m'ont instruit(e) dans les préceptes de mon art et de leur témoigner ma reconnaissance en restant fidèle à leur enseignement
, intérêt de la santé publique, ma profession avec conscience et de respecter non seulement la législation en vigueur, mais aussi les règles de l'honneur
, De ne jamais oublier ma responsabilité et mes devoirs envers le malade et sa dignité humaine
, En aucun cas, je ne consentirai à utiliser mes connaissances et mon état pour corrompre les moeurs et favoriser des actes criminels
, Que les hommes m'accordent leur estime si je suis fidèle à mes promesses
, Que je sois couvert d'opprobre et méprisé de mes confrères si j'y manque